Compare
Jade Biosciences, Inc. vs Zymeworks Inc. vs Upstream Bio, Inc. vs Capricor Therapeutics, Inc.
| Latest fiscal year | Jade Biosciences, Inc. JBIO | Zymeworks Inc. ZYME | Upstream Bio, Inc. UPB | Capricor Therapeutics, Inc. CAPR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $105.97M | $2.85M | $0 |
| Revenue growth (YoY) | n/a | +38.9% | +20.4% | -100.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -87.3% | n/m | n/a |
| Net margin | n/a | -76.6% | n/m | n/a |
| Net income | -$127.41M | -$81.13M | -$143.44M | -$105.04M |
| EPS (Diluted) | -$3.19 | -$1.08 | -$2.66 | -$2.26 |
| Operating cash flow | -$94.69M | -$33.01M | -$133.28M | -$69.81M |
| Free cash flow | -$94.89M | -$34.53M | -$133.44M | -$72.72M |
| Cash & equivalents | $88.44M | $41.16M | $101.58M | $287.85M |
| Total assets | $349.78M | $346.53M | $353.77M | $355.95M |
| Total liabilities | $17.26M | $78.03M | $14.00M | $50.16M |
| Shareholders' equity | $332.52M | $268.50M | $339.77M | $305.79M |
| Return on year-end equity | -38.3% | -30.2% | -42.2% | -34.4% |
| Shares outstanding | 49.32M | 74.64M | 54.24M | 57.37M |
Revenue, most recent five fiscal years
| Fiscal year | Jade Biosciences, Inc. | Zymeworks Inc. | Upstream Bio, Inc. | Capricor Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $105.97M Ended 2025-12-31 | $2.85M Ended 2025-12-31 | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | $76.30M Ended 2024-12-31 | $2.37M Ended 2024-12-31 | $22.27M Ended 2024-12-31 |
| 2 years earlier | n/a | $76.01M Ended 2023-12-31 | $2.38M Ended 2023-12-31 | $25.18M Ended 2023-12-31 |
| 3 years earlier | n/a | $412.48M Ended 2022-12-31 | n/a | $2.55M Ended 2022-12-31 |
| 4 years earlier | n/a | $26.68M Ended 2021-12-31 | n/a | $244.9K Ended 2021-12-31 |